Promoter hypermethylation of the tumor-suppressor genes RASSF1A, GSTP1 and CDH1 in endometrial cancer

Oncology Reports

Volumn 30, Issue 6, 2013, Pages 2878-2886

  Fiolka, Roman ^a   Zubor, Pavol ^a   Janusicova, Veronika ^a   Visnovsky, Jozef ^a   Mendelova, Andrea ^a   Kajo, Karol ^a   Lasabova, Zora ^a   Plank, Lukas ^a   Danko, Jan ^a  

^a University Hospital in Martin   (Slovakia)

Author keywords

CpG methylation; Disease risk; Endometrial cancer; Tumor suppressor gene

Indexed keywords

ADULT; ARTICLE; CANCER GRADING; CANCER RISK; CARCINOGENESIS; CDH1 GENE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; ENDOMETRIUM CANCER; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GSTP1 GENE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PELVIS LYMPH NODE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROSPECTIVE STUDY; RASSF1A GENE; TUMOR INVASION; TUMOR SUPPRESSOR GENE;

ADULT; AGED; CADHERINS; CARCINOGENESIS; CPG ISLANDS; DNA METHYLATION; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTATHIONE S-TRANSFERASE PI; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; PROMOTER REGIONS, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 84892390733     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2752     Document Type: Article

References (57)

1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D and Bray F: Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49: 1374-1403, 2013.
2. Lutz JM, Francisci S, Mugno E, Usel M, Pompe-Kirn V, Coebergh JW and Bieslka-Lasota M; EUROPREVAL Working Group: Cancer prevalence in Central Europe: the EUROPREVAL Study. Ann Oncol 14: 313-322, 2003.
3. Emons G, Fleckenstein G, Hinney B, Huschmand A and Heyl W: Hormonal interactions in endometrial cancer. Endocr Relat Cancer 7: 227-242, 2000.
4. Cirisano FD Jr, Robboy SJ, Dodge RK, Bentley RC, Krigman HR, Synan IS, Soper JT and Clarke-Pearson DL: The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma. Gynecol Oncol 77: 55-65, 2000.
5. Ito K, Utsunomiya H, Yaegashi N and Sasano H: Biological roles of estrogen and progesterone in human endometrial carcinoma - new developments in potential endocrine therapy for endometrial cancer. Endocr J 54: 667-679, 2007.
6. Gründker C, Günthert AR and Emons G: Hormonal heterogeneity of endometrial cancer. Adv Exp Med Biol 630: 166-188, 2008.
7. Armstrong AJ, Hurd WW, Elguero S, Barker NM and Zanotti KM: Diagnosis and management of endometrial hyperplasia. J Minim Invasive Gynecol 19: 562-571, 2012.
8. Sorosky JI: Endometrial cancer. Obstet Gynecol 120: 383-397, 2012.
9. Lax S: Precursor lesions of endometrial carcinoma: diagnostic approach and molecular pathology. Pathologe 32 (Suppl 2): S255-S264, 2011 (In German).
10. Tao MH and Freudenheim JL: DNA methylation in endometrial cancer. Epigenetics 5: 491-498, 2010.
11. Reinhold WC, Reimers MA, Lorenzi P, Ho J, Shankavaram UT, Ziegler MS, Bussey KJ, Nishizuka S, Ikediobi O, Pommier YG and Weinstein JN: Multifactorial regulation of E-cadherin expression: an integrative study. Mol Cancer Ther 9: 1-16, 2010.
12. Fanelli F and Raimondi F: Nucleotide binding affects intrinsic dynamics and structural communication in Ras GTPases. Curr Pharm Des 19: 4214-4225, 2012.
13. Kang J and Pervaiz S: Crosstalk between Bcl-2 family and Ras family small GTPases: potential cell fate regulation? Front Oncol 2: 206, 2012.
14. Di Domenico M, Santoro A, Ricciardi C, Iaccarino M, Iaccarino S, Freda M, Feola A, Sanguedolce F, Losito S, Pasquali D, Di Spiezio Sardo A, Bifulco G, Nappi C, Bufo P, Guida M, De Rosa G, Abbruzzese A, Caraglia M and Pannone G: Epigenetic fingerprint in endometrial carcinogenesis: the hypothesis of a uterine field cancerization. Cancer Biol Ther 12: 447-457, 2011.
15. Holliday R: The inheritance of epigenetic defects. Science 238: 163-170, 1987.
16. Jones PA: DNA methylation errors and cancer. Cancer Res 56: 2463-2467, 1996.
17. Holliday R: DNA methylation and epigenetic defects in carcinogenesis. Mutat Res 181: 215-217, 1987.
18. Jones A, Lechner M, Fourkala EO, Kristeleit R and Widschwendter M: Emerging promise of epigenetics and DNA methylation for the diagnosis and management of women's cancers. Epigenomics 2: 9-38, 2010.
19. Banno K, Kisu I, Yanokura M, Masuda K, Ueki A, Kobayashi Y, Susumu N and Aoki D: Epigenetics and genetics in endometrial cancer: new carcinogenic mechanisms and relationship with clinical practice. Epigenomics 4: 147-162, 2012.
20. Yi TZ, Li J, Han X, Guo J, Qu Q, Guo L, Sun HD and Tan WH: DNMT inhibitors and HDAC inhibitors regulate E-cadherin and Bcl-2 expression in endometrial carcinoma in vitro and in vivo. Chemotherapy 58: 19-29, 2012.
21. Lasabova Z, Tilandyova P, Kajo K, Zubor P, Burjanivova T, Danko J and Plank L: Hypermethylation of the GSTP1 promoter region in breast cancer is associated with prognostic clinicopathological parameters. Neoplasma 57: 35-40, 2010.
22. Culbova M, Lasabova Z, Stanclova A, Tilandyova P, Zubor P, Fiolka R, Danko J and Visnovsky J: Methylation of selected tumor-suppressor genes in benign and malignant ovarian tumors. Ceska Gynekol 76: 274-279, 2011 (In Slovak).
23. (INK4b) gene promoter methylation in cervical cancer patients. Oncol Lett 3: 1331-1335, 2012.
24. Silverberg SG, Kurman RJ, Nogales F, Mutter GL, Kubik-Huch RA and Tavassoli FA: Epithelial tumours and related lesions. In: Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Tavassoli FA and DeVilee P (eds). IARC Press, Lyon, pp221-232, 2003.
25. Zaino RJ, Kurman RJ, Diana KL and Morrow CP: The utility of the revised International Federation of Gynecology and Obstetrics histologic grading of endometrial adenocarcinoma using a defined nuclear grading system. A Gynecologic Oncology Group study. Cancer 75: 81-86, 1995.
26. Zaino RJ: FIGO staging of endometrial adenocarcinoma: a critical review and proposal. Int J Gynecol Pathol 28: 1-9, 2009.
27. Pecorelli S: Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 105: 103-104, 2009.
28. Herman JG, Graff JR, Myohanen S, Nelkin BD and Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93: 9821-9826, 1996.
29. House MG, Guo MZ, Iacobuzio-Donahue C and Herman JG: Molecular progression of promoter methylation in intraductal papillary mucinous neoplasms (IPMN) of the pancreas. Carcinogenesis 24: 193-198, 2003.
30. Leu YW, Rahmatpanah F, Shi H, Wei SH, Liu JC, Yan PS and Huang TH: Double RNA interference of DNMT3b and DNMT1 enhances DNA demethylation and gene reactivation. Cancer Res 63: 6110-6115, 2003.
31. Shen WJ, Dai DQ, Teng Y and Liu HB: Regulation of demethylation and re-expression of RASSF1A gene in gastric cancer cell lines by combined treatment of 5-Aza-CdR and NaB. World J Gastroenterol 14: 595-600, 2008.
32. Heichman KA and Warren JD: DNA methylation biomarkers and their utility for solid cancer diagnostics. Clin Chem Lab Med 50: 1707-1721, 2012.
33. Hatzimichael E and Crook T: Cancer epigenetics: new therapies and new challenges. J Drug Deliv 13: 529312, 2013.
34. Pallarés J, Velasco A, Eritja N, Santacana M, Dolcet X, Cuatrecasas M, Palomar-Asenjo V, Catasús L, Prat J and Matias-Guiu X: Promoter hypermethylation and reduced expression of RASSF1A are frequent molecular alterations of endometrial carcinoma. Mod Pathol 21: 691-699, 2008.
35. Fiegl H, Gattringer C, Widschwendter A, Schneitter A, Ramoni A, Sarlay D, Gaugg I, Goebel G, Müller HM, Mueller-Holzner E, Marth C and Widschwendter M: Methylated DNA collected by tampons - a new tool to detect endometrial cancer. Cancer Epidemiol Biomarkers Prev 13: 882-888, 2004.
36. Kang S, Kim JW, Kang GH, Lee S, Park NH, Song YS, Park SY, Kang SB and Lee HP: Comparison of DNA hypermethylation patterns in different types of uterine cancer: cervical squamous cell carcinoma, cervical adenocarcinoma and endometrial adenocarcinoma. Int J Cancer 118: 2168-2171, 2006.
37. Pijnenborg JM, Kisters N, van Engeland M, Dunselman GA, de Haan J, de Goeij AF and Groothuis PG: APC, beta-catenin, and E-cadherin and the development of recurrent endometrial carcinoma. Int J Gynecol Cancer 14: 947-956, 2004.
38. Arafa M, Kridelka F, Mathias V, Vanbellinghen JF, Renard I, Foidart JM, Boniver J and Delvenne P: High frequency of RASSF1A and RARb2 gene promoter methylation in morphologically normal endometrium adjacent to endometrioid adenocarcinoma. Histopathology 53: 525-532, 2008.
39. Liao X, Siu MK, Chan KY, Wong ES, Ngan HY, Chan QK, Li AS, Khoo US and Cheung AN: Hypermethylation of RAS effector-related genes and DNA methyltransferase 1 expression in endometrial carcinogenesis. Int J Cancer 123: 296-302, 2008.
40. Seeber LM, Zweemer RP, Marchionni L, Massuger LF, Smit VT, van Baal WM, Verheijen RH and van Diest PJ: Methylation profiles of endometrioid and serous endometrial cancers. Endocr Relat Cancer 17: 663-673, 2010.
41. Pijnenborg JM, Dam-de Veen GC, Kisters N, Delvoux B, van Engeland M, Herman JG and Groothuis PG: RASSF1A methylation and K-ras and B-raf mutations and recurrent endometrial cancer. Ann Oncol 18: 491-497, 2007.
42. Jo H, Kim JW, Kang GH, Park NH, Song YS, Kang SB and Lee HP: Association of promoter hypermethylation of the RASSF1A gene with prognostic parameters in endometrial cancer. Oncol Res 16: 205-209, 2006.
43. Kang S, Lee JM, Jeon ES, Lee S, Kim H, Kim HS, Seo SS, Park SY, Sidransky D and Dong SM: RASSF1A hypermethylation and its inverse correlation with BRAF and/or KRAS mutations in MSI-associated endometrial carcinoma. Int J Cancer 119: 1316-1321, 2006.
44. Zhang YQ, Mao XY, Ma XL, Zhang M and Sheng N: Effects and mechanisms of 5-aza-2'-deoxycytidine on endometrial cancer cell. Zhonghua Fu Chan Ke Za Zhi 44: 861-864, 2009 (In Chinese).
45. Yu MY, Tong JH, Chan PK, Lee TL, Chan MW, Chan AW, Lo KW and To KF: Hypermethylation of the tumor suppressor gene RASSFIA and frequent concomitant loss of heterozygosity at 3p21 in cervical cancers. Int J Cancer 105: 204-209, 2003.
46. ctn) expression in endometrial cancer and endometrial atypical hyperplasia. J Pathol 199: 471-478, 2003.
47. Saito T, Nishimura M, Yamasaki H and Kudo R: Hypermethylation in promoter region of E-cadherin gene is associated with tumor dedifferentiation and myometrial invasion in endometrial carcinoma. Cancer 97: 1002-1009, 2003.
48. Banno K, Yanokura M, Susumu N, Kawaguchi M, Hirao N, Hirasawa A, Tsukazaki K and Aoki D: Relationship of the aberrant DNA hypermethylation of cancer-related genes with carcinogenesis of endometrial cancer. Oncol Rep 16: 1189-1196, 2006.
49. Yi TZ, Guo J, Zhou L, Chen X, Mi RR, Qu QX, Zheng JH and Zhai L: Prognostic value of E-cadherin expression and CDH1 promoter methylation in patients with endometrial carcinoma. Cancer Invest 29: 86-92, 2011.
50. Graff JR, Gabrielson E, Fujii H, Baylin SB and Herman JG: Methylation patterns of the E-cadherin 5′ CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. J Biol Chem 275: 2727-2732, 2000.
51. Moreno-Bueno G, Hardisson D, Sánchez C, Sarrió D, Cassia R, García-Rostán G, Prat J, Guo M, Herman JG, Matías-Guiu X, Esteller M and Palacios J: Abnormalities of the APC/β-catenin pathway in endometrial cancer. Oncogene 21: 7981-7990, 2002.
52. Yoshiura K, Kanai Y, Ochiai A, Shimoyama Y, Sugimura T and Hirohashi S: Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc Natl Acad Sci USA 92: 7416-7419, 1995.
53. Takai N, Desmond JC, Kumagai T, Gui D, Said JW, Whittaker S, Miyakawa I and Koeffler HP: Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin Cancer Res 10: 1141-1149, 2004.
54. Hirohashi S: Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J Pathol 153: 333-339, 1998.
55. Chan QK, Khoo US, Chan KY, Ngan HY, Li SS, Chiu PM, Man LS, Ip PP, Xue WC and Cheung AN: Promoter methylation and differential expression of π-class glutathione S-transferase in endometrial carcinoma. J Mol Diagn 7: 8-16, 2005.
56. Kim GE, Kweon SS, Lee JS, Lee JH, Nam JH and Choi C: Quantitative assessment of DNA methylation for the detection of cervical and endometrial adenocarcinomas in liquid-based cytology specimens. Anal Quant Cytol Histol 34: 195-203, 2012.
57. Nieminen TT, Gylling A, Abdel-Rahman WM, Nuorva K, Aarnio M, Renkonen-Sinisalo L, Järvinen HJ, Mecklin JP, Bützow R and Peltomäki P: Molecular analysis of endometrial tumorigenesis: importance of complex hyperplasia regardless of atypia. Clin Cancer Res 15: 5772-5783, 2009.